SCHEMBL12378742

SCHEMBL12378742

Cc1ccc(C(c2ccc(C(O)c3ccccc3)cc2)C(C)c2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KEAP1 Q14145 1/20 0.41
NFE2L2 Q16236 1/20 0.41
MLKL Q8NB16 2/20 0.41
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.39
KDM4E B2RXH2 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MAPT P10636 1/20 0.39
CYP2C9 P11712 1/20 0.39
ADRA2A P08913 1/20 0.38
ADRA2C P18825 1/20 0.38
HIF1A Q16665 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL477385 0.86 LMNA (0.50) LMNATSHRHSD17B10KEAP1NFE2L2
SCHEMBL477590 0.86 LMNA (0.50) LMNATSHRHSD17B10KEAP1NFE2L2
SCHEMBL477533 0.86 LMNA (0.50) LMNATSHRHSD17B10KEAP1NFE2L2
SCHEMBL10628918 0.81 CYP2C19 (0.39) LMNATSHRKEAP1NFE2L2CYP3A4
SCHEMBL12378737 0.81 ALDH1A1 (0.48) LMNATSHRKEAP1NFE2L2KMT2A
SCHEMBL12378749 0.81 ALDH1A1 (0.57) LMNATSHRKEAP1NFE2L2KMT2A
SCHEMBL12378753 0.81 SMN1; SMN2 (0.45) LMNATSHRKEAP1NFE2L2KMT2A
SCHEMBL3863823 0.80 CA12 (0.55) LMNAMLKLCYP3A4CYP2D6CYP2C19
SCHEMBL15617630 0.80 LMNA (0.46) LMNATSHRHSD17B10KEAP1NFE2L2
SCHEMBL6548164 0.80 LMNA (0.50) LMNATSHRKEAP1NFE2L2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994372-B2 Parylene variants and methods of synthesis and use SPECIALTY COATING SYSTEMS, INC. (US) 2011-08-09 US disclosed
US-20090186998-A1 PARYLENE VARIANTS AND METHODS OF SYNTHESIS AND USE SPECIALTY COATING SYSTEMS, INC. (US) 2009-07-23 US disclosed
US-7462750-B2 Parylene variants and methods of synthesis and use SPECIALTY COATING SYSTEMS, INC. (US) 2008-12-09 US disclosed
US-20070099019-A1 Parylene variants and methods of synthesis and use SPECIALTY COATING SYSTEMS, INC. (US) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099019-A1 Parylene variants and methods of synthesis and use CDC73, PARN, PFAS LMNA 514/4885TSHR 2174/4885HSD17B10 2272/4885
US-20090186998-A1 PARYLENE VARIANTS AND METHODS OF SYNTHESIS AND USE CDC73, PARN, PFAS LMNA 632/4885TSHR 2311/4885HSD17B10 1870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.